Beata Polkowska-Pruszyńska

Dr. Beata Polkowska-Pruszyńska

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2019 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
BPBeata Polkowska-Pruszyńska
Beata Polkowska-Pruszyńska
AGA. Gerkowicz
A. Gerkowicz
Dorota KrasowskaDorota Krasowska
Dorota Krasowska

31 October 2018 in Archives of Dermatological Research
Verified
Journal Article
Open access
PDF file
BPBeata Polkowska-Pruszyńska
Beata Polkowska-Pruszyńska
AGAgnieszka Gerkowicz
Agnieszka Gerkowicz
PSPaulina Szczepanik-Kułak
Paulina Szczepanik-Kułak
Dorota KrasowskaDorota Krasowska
Dorota Krasowska
Systemic sclerosis (SSc) is a chronic, connective tissue disease with an autoimmune pattern characterized by inflammation, fibrosis and microcirculation changes leading to internal organs malfunctions. Recently, the presence of uncharacteristic gastrointestinal symptoms in the course of SSc has been underlined. The possible cause of such clinical presentation is the small intestinal bacterial overgrowth (SIBO). Nevertheless, these manifestations resulting from gastrointestinal tract hypomotility may occur in numerous disease entities. The systematic review of the literature was performed on MEDLINE database using the relevant MeSH terms including all sub-headings. After further investigation, the initial number of 56 records was limited to 7 results. The study analysis showed an increased presence of SIBO in 39% of patients suffering from SSc. The average SSc duration was longer in SSc patients with coexisting SIBO. SIBO remains a diagnostic and therapeutic challenge and therefore is a significant clinical problem among patients suffering from SSc.

13 September 2017 in Archives of Dermatological Research
Verified
Journal Article
Open access
PDF file
DPDaniel Pietrzak
Daniel Pietrzak
APAldona Pietrzak
Aldona Pietrzak
Dorota KrasowskaDorota Krasowska
Dorota Krasowska
ABAndrzej Borzęcki
Andrzej Borzęcki
KFKinga Franciszkiewicz-Pietrzak
Kinga Franciszkiewicz-Pietrzak
KRKristian Reich
Kristian Reich
Psoriasis is a chronic inflammatory immune-mediated disorder associated and often coexisting with many other immune-related clinical conditions including those affecting the gastrointestinal tract. Data obtained from the reviewed literature suggest an association between psoriasis and pathologies of the oral cavity, both psoriasis-specific lesions, as well as non-specific, such as geographic tongue or fissured tongue. These findings show the importance of thorough examination of oral mucosa in psoriatic patients. Inflammatory bowel diseases (IBD) are also linked with psoriasis. Crohn’s disease and ulcerative colitis share a common genetic background, inflammatory pathways and have an evident iatrogenic anti-TNF treatment link, necessitating dermatological or gastroenterological care in patients with IBD or psoriasis, respectively, as well as treatment adjusted to manifestations. The presence of celiac disease-specific antibodies in psoriatic patients and their correlation with the severity of the disease show the association between these disorders. The linking pathogenesis comprises vitamin D deficiency, immune pathway, genetic background and increase in the intestinal permeability, which suggests a potential benefit from gluten-free diet among psoriatic patients. The link between psoriasis and non-alcoholic fatty liver disease implies screening patients for components of metabolic syndrome and lifestyle changes necessity. Some studies indicate increased prevalence of cancer in patients with psoriasis, probably due to negative influence of skin lesion impact on lifestyle rather than the role of psoriasis in carcinogenesis. However, there are no sufficient data to exclude such an oncogenic hit, which is yet to be confirmed. Therefore, all psoriasis-associated comorbidities establish the importance of a multidisciplinary approach in the treatment of these patients.

13 August 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
BPBeata Polkowska-Pruszyńska
Beata Polkowska-Pruszyńska
AGAgnieszka Gerkowicz
Agnieszka Gerkowicz
KRKarol Rawicz-Pruszyński
Karol Rawicz-Pruszyński
Dorota KrasowskaDorota Krasowska
Dorota Krasowska
Fecal calprotectin (FC) is a quick, cost-effective, and noninvasive test, which is used to diagnose patients with active inflammatory bowel diseases (IBD). Recent studies suggest the possible predictive role of FC in the diagnosis of small intestinal bacterial overgrowth (SIBO) in patients with systemic sclerosis (SSc). This study aimed to assess the predictive value of FC in SSc patients and its’ possible use as a SIBO marker. A total of 40 SSc patients and 39 healthy volunteers were enrolled in the study. All subjects completed questionnaires evaluating gastrointestinal symptoms, FC measurements, and lactulose hydrogen breath test (LHBT) assessing SIBO presence. After rifaximin treatment, patients with SIBO underwent the same diagnostic procedures. Significantly higher FC values were observed in the study group compared to controls (97 vs. 20 μg/g; p < 0.0001) and in SSc patients diagnosed with SIBO compared to SSc patients without SIBO (206 vs. 24 μg/g; p = 0.0010). FC turned out to be a sensitive (94.12%) and specific (73.68%) marker in the detection of SIBO in patients with SSc (AUC = 0.82, 95% CI = 0.66–0.93; p < 0.0001). Our study suggests the potential value of FC in SSc in detecting gastrointestinal impairment and its promising role as an additional diagnostic tool for SIBO.

1 January 2022 in Advances in Dermatology and Allergology
Verified
Journal Article
Open access
BPBeata Polkowska-Pruszyńska
Beata Polkowska-Pruszyńska
AGAgnieszka Gerkowicz
Agnieszka Gerkowicz
KRKarol Rawicz-Pruszyński
Karol Rawicz-Pruszyński
Dorota KrasowskaDorota Krasowska
Dorota Krasowska
Introduction Systemic sclerosis (SSc) is a chronic, connective tissue disease characterized by inflammation, fibrosis and microcirculation disturbances. Gastrointestinal involvement and impaired gut motility observed in SSc promotes the small intestinal bacterial overgrowth (SIBO) defined as...

10 October 2017 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
DPDaniel Pietrzak
Daniel Pietrzak
APAldona Pietrzak
Aldona Pietrzak
DKDorota Krasowska
Dorota Krasowska
ABAndrzej Borzęcki
Andrzej Borzęcki
KFKinga Franciszkiewicz-Pietrzak
Kinga Franciszkiewicz-Pietrzak
KRKristian Reich
Kristian Reich